Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial

Clinical and experimental rheumatology

Volumn 32, Issue 6, 2014, Pages

  Gordon, J ^a   Udeh, U ^a   Doobay, K ^a   Magro, C ^a   Wildman, H ^a   Davids, M ^a   Mersten, J N ^a   Huang, W T ^a   Lyman, S ^a   Crow, M K ^a   Spiera, R F ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BENZAMIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMATINIB; PIPERAZINE DERIVATIVE; PREDNISONE; PROTEIN KINASE INHIBITOR; PROTON PUMP INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; FEMALE; HUMAN; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; BENZAMIDES; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; IMATINIB MESYLATE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PIPERAZINES; PREDNISONE; PROTEIN KINASE INHIBITORS; PROTON PUMP INHIBITORS; PYRIMIDINES; RESPIRATORY FUNCTION TESTS; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

EID: 85006237832     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)